Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

753958

	registered interest
	date	19/07/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radioisotopes: Imports
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government (1) what assessment they have made of the potential impact of not reaching agreement with the EU by April 2019 on the supply of the radioisotope molybdenum-99 used to produce technetium-99m which is required for over 80 per cent of diagnostic medicine procedures in the UK; (2) what assessment they have made of the potential impact of delays or disruption to the supply of diagnostic medicine procedures that may result; and (3) what contingency plans they have put in place to mitigate such delays or disruption to that supply after Brexit.
	tabling member printed	Lord Mendelsohn
	uin	HL1104
	answer	answer is ministerial correction date of answer 31/07/2017 answer text <p>The Government is fully aware of the importance of molybdenum-99 and the reliance on this medical radioisotope for diagnostic procedures in the National Health Service. The United Kingdom’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom. It is in everyone’s interest to not disrupt the timely access of treatment to patients and to ensure that cross-border trade with the European Union and Euratom is as frictionless as possible.</p> answering member printed Lord O'Shaughnessy question first answered 31/07/2017 13:38:56 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

753959

	registered interest
	date	19/07/2017
	answering body	Department for Exiting the European Union
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	hansard heading	Radioisotopes: Imports
	house id	2
	legislature	25277 pref label House of Lords
	question text	Her Majesty's Government what terms they are seeking to agree with the European Union to ensure that no additional delays or restrictions are placed on imports of molybdenum-99 to the UK following the UK's departure from Euratom.
	tabling member printed	Lord Mendelsohn
	uin	HL1105
	answer	answer is ministerial correction date of answer 02/08/2017 answer text <p>The UK’s ability to import medical isotopes from Europe and the rest of the world will not be affected by withdrawal from Euratom.</p><p>The import or export of medical radioisotopes, including molybdenum-99 is not subject to any Euratom licensing requirements.These isotopes are governed and regulated under the Euratom framework; however, Euratom places no restrictions on the export of medical isotopes to countries outside the EU.</p><p>It is in everyone’s interest to not disrupt the timely access of treatment to patients; and to ensure that cross-border trade with the EU and Euratom is as frictionless as possible.</p><p> </p> answering member printed Baroness Anelay of St Johns question first answered 02/08/2017 14:39:06 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	4286 label Biography information for Lord Mendelsohn

993365

	registered interest
	date	22/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government (1) how many drugs were available on the NHS for the treatment of blood cancer, and (2) how much the NHS spent on blood cancer drugs, in each of the past five years.
	tabling member printed	Lord Mendelsohn
	uin	HL10893
	answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>NHS England has advised that it is not possible to provide a comprehensive list of drugs that are available specifically for blood cancer or how much the National Health Service spends on blood cancer drugs as cancer drugs are often licenced for multiple different types of cancer.</p> answering member printed Lord O'Shaughnessy question first answered 05/11/2018 14:29:39 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

922991

	registered interest
	date	12/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Leukaemia: Ibrutinib
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government (1) what evidence NHS England considered, (2) which clinicians it consulted, and (3) which patient groups it consulted when deciding that ibrutinib should not be prescribed to people with chronic lymphocytic leukaemia who have been in remission for more than three years.
	tabling member printed	Lord Mendelsohn
	uin	HL8564
	answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL8561 HL8562 HL8563 question first answered 26/06/2018 12:13:53 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

885902

	registered interest
	date	17/04/2018
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Artificial Intelligence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government by what metrics they will determine whether the UK has become “the go-to destination for AI innovation and investment”, as set out in their Industrial Strategy White Paper; and by what date they intend to achieve that aim.
	tabling member printed	Lord Mendelsohn
	uin	HL6996
	answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>AI is emerging in its own right as a nascent industry with the potential to raise the productivity of diverse sectors and create entirely new jobs. To maximise this potential, the recently announced AI Sector Deal will establish a new AI Council to bring together respected leaders in the field from across academia and industry; a new delivery body within the government – the Office for Artificial Intelligence – to support it; and a new Centre for Data Ethics and Innovation.</p><p> </p><p>Oversight of the implementation of the Sector Deal will be led by the Office for Artificial Intelligence, which will review progress against objectives regularly.</p><p> </p><p>The new government Office for Artificial Intelligence will be established with responsibility for implementing this Sector Deal. It will support the AI Council which will oversee and drive the implementation of the deal.</p><p> </p><p>An early role for the Office for AI will be to agree implementation plans for each section of the deal, including agreed success metrics.</p><p> </p><p>Membership of the AI Council will be announced ahead of the first meeting. The main aim of the AI Council will be to provide strategic leadership and momentum in delivery.</p><p> </p><p>The Office for AI will report to the AI Council regularly and will be subject to challenge sessions from government ministers on progress in implementing the Sector Deal. The Industrial Strategy team will provide the challenge on delivery timetable, metrics and ambition on outcomes as well as providing updates and escalation to ministers across the suite of Sector Deals.</p> answering member printed Lord Henley question first answered 30/04/2018 16:38:54 answering member 2616 label Biography information for Lord Henley
	tabling member	4286 label Biography information for Lord Mendelsohn

788337

	registered interest
	date	13/11/2017
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Small Businesses: Complaints
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government further to the Written Answer by Lord Henley on 10 November (HL2702), how many complaints from small businesses have been received by (1) the Department for Business, Energy and Industrial Strategy, and (2) the Small Business Commissioner's office, since 1 October; and of those, how many have not been accepted because of the delay in the launch of the Small Business Commissioner's complaints handling service.
	tabling member printed	Lord Mendelsohn
	uin	HL3129
	answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>Since 1 October, the Department for Business Energy &amp; Industrial Strategy has not received any complaints from small businesses that would be in scope of the proposed Small Business Commissioner’s complaints handling service. The office of the Small Business Commissioner has received two enquiries on behalf of small businesses, neither of which would be in scope of the proposed complaints handling service. Secondary legislation relating to this complaints handling service is currently before this House, and would need to come into force before the complaints service could launch. Subject to the will of Parliament, when it is in force small businesses will be able to submit complaints for consideration, including complaints relating to the period from 6 April 2017.</p> answering member printed Lord Henley question first answered 20/11/2017 15:17:54 answering member 2616 label Biography information for Lord Henley
	tabling member	4286 label Biography information for Lord Mendelsohn

922989

	registered interest
	date	12/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how NHS England formulates approval criteria for drugs already approved by the National Institute for Health and Clinical Excellence; and how it involves (1) patients, and (2) clinicians in this process.
	tabling member printed	Lord Mendelsohn
	uin	HL8562
	answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL8561 HL8563 HL8564 question first answered 26/06/2018 12:13:53 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

767939

	registered interest
	date	10/10/2017
	answering body	Department for Exiting the European Union
	answering dept id	203
	answering dept short name	Exiting the European Union
	answering dept sort name	Exiting the European Union
	hansard heading	Regulation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many EU-level regulatory bodies they anticipate will require the establishment of a new UK-level body as a result of the UK's departure from the EU and the conversion of EU law into UK law; and by what date they plan to have those bodies established.
	tabling member printed	Lord Mendelsohn
	uin	HL1858
	answer	answer is ministerial correction date of answer 23/10/2017 answer text <p>No decisions have yet been taken on our future relationship with the EU's regulatory bodies after exiting the EU. We are carefully considering a range of options and preparing for a number of negotiation outcomes.</p><p>Prior to any decisions on establishing new UK-level bodies, the Government will, however, always look to minimise disruption and costs, which will include considering alternative options. The European Union (Withdrawal) Bill makes clear that any decision on creating new agencies would require the approval of both Houses of Parliament under the affirmative procedure.</p><p>We will continue to plan for a range of scenarios and be ready to take any necessary steps to ensure that we are ready for exit day.</p><p> </p> answering member printed Baroness Anelay of St Johns question first answered 23/10/2017 11:50:07 answering member 3474 label Biography information for Baroness Anelay of St Johns
	tabling member	4286 label Biography information for Lord Mendelsohn

922990

	registered interest
	date	12/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many Individual Funding Requests have been submitted to the NHS for the treatment of blood cancer; and of those, how many requests were (1) successful, and (2) unsuccessful.
	tabling member printed	Lord Mendelsohn
	uin	HL8563
	answer	answer is ministerial correction date of answer 26/06/2018 answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p> answering member printed Lord O'Shaughnessy grouped question UIN HL8561 HL8562 HL8564 question first answered 26/06/2018 12:13:53 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4286 label Biography information for Lord Mendelsohn

780337

	registered interest
	date	30/10/2017
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Small Businesses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many civil servants in (1) the Department for Business, Energy and Industrial Strategy, and (2) the Department for International Trade, were responsible for small business policy in each year since 2010, broken down by grade.
	tabling member printed	Lord Mendelsohn
	uin	HL2701
	answer	answer is ministerial correction date of answer 10/11/2017 answer text <p>Both the Department for Business, Energy and Industrial Strategy and the Department for International Trade have staff working in a wide range of policy development and delivery activities which support small businesses across the UK. The information is not held centrally and could only be provided at disproportionate costs.</p> answering member printed Lord Henley question first answered 10/11/2017 12:50:39 answering member 2616 label Biography information for Lord Henley
	tabling member	4286 label Biography information for Lord Mendelsohn